# A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

> **NCT00241449** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 51 (actual)

## Conditions studied

- Breast Cancer
- Metastasis

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00241449
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** 2007-03
- **Final completion:** 2012-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00241449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00241449, "A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00241449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*